Brea C. Lipe, MD closes this series highlighting the vast landscape of effective treatments and those on the horizon.
Summary
Brea C. Lipe, MD concludes this series reflecting on the data from the PERSEUS trial. The emergence of highly effective upfront regimens like DARA-VRd is not just expanding options but providing time - time for new treatments to become available, and time to optimize treatment sequencing. These potent combinations are extending survival so dramatically that it allows us to figure out ideal ways to leverage the many tools now available. Patients living longer is wonderful, but also an opportunity to carefully tailor regimens to each patient to enable them to live their best quality life. The variability seen in the data further demonstrates we can individualize modern regimens to meet patients where they are. With strong, tolerable regimens profoundly extending life, we can focus on mitigating side effects and keeping patients on treatment. The bottom line is today's excellent upfront options are a bridge to continued progress, buying time to optimize care until the next wave of advances. This is an exciting point in time for the myeloma field and for patients.
Summary was AI-generated and edited for clarity.
Khouri Discusses Selinexor Dosing and Management Approaches for R/R MM
July 22nd 2024During a Case-Based Roundtable® event, Jack Khouri, MD, and participants discussed the use of selinexor with dose modifications to manage toxicity in patients with relapsed/refractory multiple myeloma.
Read More
New Hope for Multiple Myeloma: Cilta-Cel Improves Overall Survival
July 2nd 2024The CARTITUDE-4 study that found that treatment with cilta-cel led to a statistically significant and clinically meaningful improvement in overall survival among patients with relapsed and lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.
Read More